Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 1Hepatic Veno-Occlusive Disease 1Colorectal Neoplasms 1Chemical and Drug Induced Liver Injury 1

Interventions

pembrolizumab 512Specimen Handling 381Carboplatin 371Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 302Cyclophosphamide 295Radiotherapy 254Paclitaxel 252Biopsy 235Gemcitabine 229Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 154Rituximab 151Fluorouracil 148venetoclax 142atezolizumab 141Docetaxel 141Drug Therapy 140Etoposide 138Doxorubicin 131Ipilimumab 125Radiosurgery 118Lenalidomide 117Prednisone 116Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × S-Adenosylmethionine × 1 year × Clear all
NCT06258525 2026-05-06

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
30 enrolled
Classical hematologyGastrointestinal

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

NCT07495995 2026-03-31

SAMeMASLDc-02

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
94 enrolled

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡